Chemotherapy combined regimens has prolonged the survival of advanced or metastatic cancer patients, by targeting some of the enzymes involved in the metabolic process of 5-fluorouracil (5-FU), such as TS, DPD, and 2′-deoxyuridine-5′triphosphate nucleotidohydrolase (dUTPase), whose inhibition prevents drug catabolism, enhancing the efficacy of TS inhibition by increasing 5-fluorodeoxyuridine-5′-triphosphate (FdUTP) incorporation into DNA (Wilson et al., 2014). Here, TYMS is linked to metastatic malignant neoplasm.